US: 1.917.963.8646 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Global Intravenous Iron Drugs Market 2021: By product type (Iron dextran, Iron sucrose, Ferric carboxymaltose), By application (Chronic kidney disease (CKD), Inflammatory bowel disease (IBD), Cancer)Global Intravenous Iron Drugs Market is a recent report generated by Trusted Business Insights. The study and analysis were administered using expert opinions and inputs, as well as thorough primary and secondary research efforts to determine various aspects of the intravenous iron drugs market. The market segmentation allows for deeper thought and understanding in order to strongly assess, analyze, and study. Besides revenues for segments, the global, regional, and country-wise market revenue segmentation has been compiled in a veracious manner for clear understanding and flow. The Global Intravenous Iron Drugs market size was valued at USD $2.3 Billion in 2020, USD $2.5 Billion in 2021, forecasted to reach USD $2.71 Billion in 2022, and is projected to reach USD $5.2 Billion by 2030, and is anticipated to expand at a CAGR of 8.5% over the forecast period from 2020 to 2030. Overview: A vital component of hemoglobin, iron plays a key role in transporting oxygen throughout our bodies. Iron infusion is a procedure by which iron is intravenously (delivered to the body through the veins) administered to a person. The method by which this is delivered is known as an IV or intravenous infusion. This is done by doctors for patients that are unable to consume iron supplements either – orally, cant adequately absorb it through the gut, lack of iron due to loss of blood, or by those that need to increase their iron levels quickly to avoid medical complications. It is usually prescribed to treat iron deficiency anemia. It is known to be unsuitable for those in their first trimester and is usually more expensive than oral forms of therapy. Dynamics: The global intravenous iron drugs market is slated to grow at a high CAGR over the forecast time period from its valuation of $US 1.63 billion in 2018. The reasons for this growth have been linked to the increasing number of dialysis patients, a surge in chronic kidney disease patients and the rising geriatric population. Additionally, increased healthcare investments, higher medical expenditures, and an escalating number of iron deficiency anemia cases will aid the growth of this market. A few considerable side-effects are – muscle cramps, nausea, vomiting, coughing, and joint & back pain as well as constipation. These various related side-effects and stringent guidelines imposed by the respective authorities may hamper the growth of the global intravenous iron drugs market. The process of approval and the requirement to comply with several regulations may hinder the expansion of this market. On the basis of product type, this market is sectioned into – ferric carboxymaltose, iron dextran, iron sucrose as well as other products. Due to its increased application in drug discovery, reduced cost, and superior performance, the ferric carboxymaltose segment occupied the largest share of the market in 2018 and is expected to continue to do so over the forecast period. The segment for iron sucrose had the second-largest share of the market, followed by products like ferumoxytol and ferric maltol. In terms of application, the intravenous iron drugs market is segmented into chronic kidney disease (CKD), cancer and inflammatory bowel disease, among others. The largest market share in 2018 was accounted for by the chronic kidney disease segment. Some factors that are the cause of this are a general inclination towards a sedentary lifestyle and a growing geriatric population. The segment for cancer is slated to establish the quickest growth over the forecasted tenure due to its very high incidence rates. Regional Analysis: The global intravenous iron drugs market is extremely competitive thanks to the presence of established companies and the emergence of new ones. Large market shares in 2018 were held by Daiichi Sankyo Company, AMAG Pharmaceuticals, Vifor Pharma, and Pharmacosmos respectively. This was due to a wide geographical presence and an extensive product portfolio. Several strategies such as mergers & acquisitions, new product development, regional expansions, and strategic partnerships have been undertaken to achieve a competitive edge in the market. Emerging markets like Japan, China, South Korea, and India are projected to achieve significant levels of growth during the forecast period.
Below are the leading companies profiled in this Intravenous Iron Drugs Market Report:
Chapter 1 Methodology and Scope